



AlloVir to Present at the 39th Annual J.P. Morgan Healthcare Conference

January 4, 2021

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 4, 2021-- AlloVir, Inc. (Nasdaq: ALVR), a late clinical-stage cell therapy company, will present a corporate overview at the 39th Annual J.P. Morgan Healthcare Conference on January 11, 2021 at 9:10 a.m. ET.

An audio-only webcast of the presentation will be available on January 11th on the Investors & Press section of the AlloVir website at <https://ir.allovir.com>. An archived replay of the presentation will be available for approximately 30 days following the presentation.

About AlloVir

AlloVir is a leading late clinical-stage cell therapy company with a focus on restoring natural immunity against life-threatening viral diseases in patients with weakened immune systems. The company's innovative and proprietary technology platforms leverage off-the-shelf, allogeneic, multi-virus specific T cells targeting devastating viruses for patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. AlloVir's technology and manufacturing process enables the potential for the treatment and prevention of a spectrum of devastating viruses with each single allogeneic cell therapy. The company is advancing multiple mid- and late-stage clinical trials across its product portfolio. For more information visit www.allovir.com.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20210104005013/en/): <https://www.businesswire.com/news/home/20210104005013/en/>

Media:

Courtney Heath
ScientPR

AlloVirPR@scientpr.com

617-872-2462

Investors:

Medha Chadha
AlloVir

ir@allovir.com

Source: AlloVir, Inc.